Axon Enterprise Inc vs Medtronic PLC — how do they compare? Axon Enterprise Inc trades at $601.09 (market cap $51.69B), while Medtronic PLC trades at $90.44 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 2.2× Axon Enterprise Inc's market cap, and Medtronic PLC pays a 3.18% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | MDT | |
|---|---|---|
Market Cap | $51.69B | $116.07B |
Sector | Technology | Health |
52-Week High | $791.62 | $105.35 |
52-Week Low | $345.94 | $73.75 |
Enterprise Value | $52.83B | $134.82B |
Dividend Yield | — | 3.18% |
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.
Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →